BMC Medicine · 2016 · 49 citations · 14 references
Public HealthInfectious Disease ControlInfectious DiseasesAntimicrobial ResistanceGood Laboratory PracticeTuberculosis ControlMycobacterial DiagnosticsTuberculosis CareTuberculosis DiagnosisTuberculosis Diagnostic TestingTuberculosis EpidemiologyTuberculosis SurveillanceDrug Resistance TestingLaboratory InfrastructureMycobacterial DiagnosisMycobacterial DiseaseResistance PrevalenceSputum Smear MicroscopyTuberculosis Drug ResistanceTuberculosis Molecular Testing
BACKGROUND: Drug-resistant tuberculosis (TB) is a global public health problem. Adequate management requires baseline drug-resistance prevalence data. In West Africa, due to a poor laboratory infrastructure and inadequate capacity, such data are scarce. Therefore, the true extent of drug-resistant TB was hitherto undetermined. In 2008, a new research network, the West African Network of Excellence for Tuberculosis, AIDS and Malaria (WANETAM), was founded, comprising nine study sites from eight West African countries (Burkina Faso, The Gambia, Ghana, Guinea-Bissau, Mali, Nigeria, Senegal and Togo). The goal was to establish Good Clinical Laboratory Practice (GCLP) principles and build capacity in standardised smear microscopy and mycobacterial culture across partnering laboratories to generate the first comprehensive West African drug-resistance data. METHODS: Following GCLP and laboratory training sessions, TB isolates were collected at sentinel referral sites between 2009-2013 and tested for first- and second-line drug resistance. RESULTS: From the analysis of 974 isolates, an unexpectedly high prevalence of multi-drug-resistant (MDR) strains was found in new (6 %) and retreatment patients (35 %) across all sentinel sites, with the highest prevalence amongst retreatment patients in Bamako, Mali (59 %) and the two Nigerian sites in Ibadan and Lagos (39 % and 66 %). In Lagos, MDR is already spreading actively amongst 32 % of new patients. Pre-extensively drug-resistant (pre-XDR) isolates are present in all sites, with Ghana showing the highest proportion (35 % of MDR). In Ghana and Togo, pre-XDR isolates are circulating amongst new patients. CONCLUSIONS: West African drug-resistance prevalence poses a previously underestimated, yet serious public health threat, and our estimates obtained differ significantly from previous World Health Organisation (WHO) estimates. Therefore, our data are reshaping current concepts and are essential in informing WHO and public health strategists to implement urgently needed surveillance and control interventions in West Africa.
14
Policy Guidance on Drug-Susceptibility Testing (DST) of Second-Line Antituberculosis Drugs
L Barrera, E Cooreman, de Dieu Iragena J et al. · 2008 · 227 citations
Alberto Piubello, Souleymane Hassane Harouna, Mahamadou Bassirou Souleymane et al. · The International Journal of Tuberculosis and Lung Disease · 2014 · 225 citations
Fausta Ardito, Brunella Posteraro, Maurizio Sanguinetti et al. · Journal of Clinical Microbiology · 2001 · 122 citations · Full text
Veterinary Medicine, Pharmacology, Clinical Pharmacology +14